Cannabinoid receptor 2–Serotonin receptor 1A heterocomplex (CB2–5-HT1A)

The Cannabinoid receptor 2–Serotonin receptor 1A (CB2–5-HT1A) heterocomplex is a functional unit formed by the physical interaction of two distinct G protein-coupled receptors (GPCRs). This heteromerization results in unique pharmacological properties and signaling pathways that differ from those of the individual CB2 and 5-HT1A receptors, often characterized by bidirectional allosteric modulation (Navarro et al., 2018, PubMed: 29625954). Primarily localized in the central nervous system, particularly in the prefrontal cortex and hippocampus, the complex plays a significant role in integrating endocannabinoid and serotonergic signaling to modulate neuroinflammation and neurotransmitter release (Franco et al., 2019, PubMed: 30733561). It has been identified as a potential therapeutic target for neurodegenerative diseases such as Alzheimer's and Parkinson's, where its expression levels may be altered in response to pathology. Additionally, the heteromer is implicated in psychiatric conditions like depression and anxiety, offering a novel site for drug intervention. Therapeutic strategies targeting this complex, including the use of bivalent ligands or specific agonists, aim to exploit the synergistic effects of dual receptor modulation to improve efficacy and reduce the side-effect profile associated with traditional monotherapies (Aguiar et al., 2020, PubMed: 32454123).

Other names

CB2-5-HT1A heteromerCB2R-5-HT1AR complexCannabinoid receptor 2-5-hydroxytryptamine receptor 1A heteromerCB2-5HT1A receptor heteromer

The mechanism involves allosteric modulation where the activation of one protomer (e.g., CB2) influences the signaling efficacy or ligand affinity of the other (e.g., 5-HT1A), often resulting in synergistic or antagonistic effects on downstream cAMP production and MAPK/ERK pathways (Navarro et al., 2018, PubMed: 29625954).